Clinical Trial Update: Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of saracatinib in patients with relapsed or refractory thymoma or thymic carcinoma was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma
• Thymoma

Drugs mentioned

• Saracatinib (saracatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Invasive Thymoma and Thymic Carcinoma, Recurrent Thymoma and Thymic Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2015-06-10